retatrutide triple agonist glp-1 gip glucagon Mounjaro: Retatrutide and Diabetes

Retatrutide is a triple-agonist drug targeting GLP-1, GIP, and glucagon receptors to suppress appetite and boost thermogenesis. Phase 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing

29.15

★★★★☆4.8 (126)

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

20.57

★★★★★4.9 (98)

Retatrutide (40mg)

25.60

★★★★★5.0 (157)

Retatrutide. The triple agonist that's redefining metabolic research. 🧬 One compound. Three receptors. Unprecedented research potential. GIP → insulin response research GLP-1 → appetite suppression studies Glucagon → energy expenditure modulation No

22.50

★★★★★4.7 (84)

Hitting the Triple G Spot: The New Triple G Agonist for Weight Loss

21.33

★★★★★4.9 (203)

🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in

24.55

★★★★★5.0 (176)

Triple G Agonists – Retatrutide. What is all the buzz? – Dr Girouard's

27.34

★★★★★4.8 (132)